|1.||Gutiérrez, José María: 12 articles (04/2015 - 06/2005)|
|2.||Rucavado, Alexandra: 10 articles (04/2015 - 06/2005)|
|3.||Bond, Judith S: 10 articles (03/2014 - 01/2003)|
|4.||Vizoso, Francisco J: 10 articles (03/2014 - 01/2008)|
|5.||Fox, Jay W: 9 articles (04/2015 - 06/2005)|
|6.||Escalante, Teresa: 9 articles (04/2015 - 06/2005)|
|7.||González, Luis O: 9 articles (03/2014 - 09/2009)|
|8.||Newby, Andrew C: 8 articles (05/2015 - 05/2003)|
|9.||López-Otín, Carlos: 8 articles (05/2015 - 06/2009)|
|10.||Edwards, Dylan R: 8 articles (01/2013 - 04/2004)|
01/01/2012 - "These studies have been further expanded by large-scale genomic analysis, revealing that the genes encoding metalloproteinases, such as MMP8, MMP27, ADAM7, and ADAM29, are recurrently mutated in specific tumors, while several ADAMTSs are epigenetically silenced in different cancers. "
10/01/2010 - "Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study."
05/01/2010 - "In this context, the aim of this work was to study the differential expression of metalloproteinases and adhesion molecules related to cancer invasiveness in both groups of tumours. "
06/01/2009 - "However, recent functional studies have revealed that some metalloproteases, including several members of the ADAMTS family, also exhibit tumor suppressor properties. "
09/03/1999 - "Our previous studies have shown that CD44 expressed in cancer cells is proteolytically cleaved at the extracellular domain through membrane-associated metalloproteases and that CD44 cleavage plays a critical role in CD44-mediated tumor cell migration (Okamoto, I., Kawano, Y., Tsuiki, H., Sasaki, J., Nakao, M., Matsumoto, M., Suga, M., Ando, M., Nakajima, M., and Saya, H. "
01/01/2015 - "Long-term cPAP improved endothelial function and hemorheology, reduced oxidative stress and inflammation, and decreased the levels of metalloproteases."
12/01/2008 - "Previous studies showed increased metalloproteinases (MMP) level, especially MMP-9, as a sign of local inflammation. "
12/01/2005 - "The main hypothesis to be tested in this study was that metallopeptidases and kinin receptors are present in oropharyngeal tissues and that their expression is modulated by ACEi and inflammation. "
09/01/2015 - "Appropriately, pharmacological agents such as inhibitors of inflammation, antithrombin and inhibitors of metalloproteases display potential to attenuate shedding of the glycocalyx in various experimental models. "
01/01/2015 - "Stanford-A acute aortic dissection, inflammation, and metalloproteinases: a review."
01/01/2016 - "Specific analysis on metalloproteases and their inhibitors underscored unexpected mechanisms potentially involved in renal fibrosis. "
12/01/2013 - "Disintegrin metalloproteases (Adam) can manipulate the signaling environment, however, the role and regulation of ADAMs in renal fibrosis remain unclear. "
07/01/2012 - "Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 (TIMPs -1 and -2) in fibroblasts are early indicators of oral sub-mucous fibrosis and ageing."
07/01/2012 - "In vitro, E2 directly inhibited ANG II-induced expression of fibrosis markers as well as the metalloproteinases in cultured cardiac fibroblasts. "
01/01/2012 - "Therapeutic monitoring of TGF-β and metalloproteases provides important insights into fibrosis."
|4.||Neoplasm Metastasis (Metastasis)
11/01/2014 - "The number of invadopodia positively correlated with degradation, while the inhibiting metalloproteases eliminated degradation and lung metastasis, consistent with a direct link among invadopodia, ECM degradation, and metastasis. "
01/01/2015 - "Consistently, the activities of metastasis-associated metalloproteinases MMP-2 and MMP-9 were attenuated in BubR1 knockdown Ca9-22 cells, suggesting the role of BubR1 in promotion of OSCC migration. "
04/15/2014 - "Metalloproteases regulate a vast array of critical cellular processes such as proliferation, migration, repair, and invasion/metastasis. "
01/01/2011 - "The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis."
01/01/2008 - "The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis."
07/15/1998 - "Clinical trials with specific inhibitors of metalloproteinases are beginning in osteoarthritis."
09/01/2014 - "One of the mechanisms of cartilage degradation in osteoarthritis is enzymatic proteolysis of the extracellular matrix by metalloproteinases. "
01/01/2013 - "Osteoarthritis is characterised by progressive loss of articular cartilage through the increase of catabolic metalloproteinases, and chondrocyte cytoskeleton disruption has also been reported. "
11/01/2009 - "Metalloproteinases in osteoarthritis]."
02/01/2007 - "Molecular targets in osteoarthritis: metalloproteinases and their inhibitors."
|2.||Tissue Inhibitor of Metalloproteinases (TIMP)
|4.||Messenger RNA (mRNA)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|8.||Snake Venoms (Snake Venom)
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Transplantation (Transplant Recipients)
|4.||Homologous Transplantation (Allograft)